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Abstract
Background: The incidence of type 2 diabetes is increasing, creating a huge burden for China’s social healthcare
system. This study aimed to evaluate hospital length of stay (LOS) based on admission characteristics and direct
costs correlated with various types of complications for type 2 diabetic inpatients in Hubei Province, China.
Methods: A total of 1528 inpatients diagnosed with type 2 diabetes discharged between April 1, 2013, and March
31, 2014, were included in this study. Information regarding patients’ admission and hospitalization were obtained
from the hospital information system. The relationship between admission characteristics and LOS, distribution of
total costs, and types of complications were described and analysed.
Results: (1) The mean LOS was 11.65 days (median: 10 days). Multiple linear regression analysis demonstrated that
inpatients with New Cooperative Medical Scheme (NCMS), aged 80 and above, had longer LOS than the reference
group, and inpatients with chronic or acute + chronic complications had shorter LOS than those without. (2) Mean
total costs per patient were US$159.72 ± 130.83 (median: US$135.33), US$240.60 ± 166.58 (median: US$192.09), and
US$247.98 ± 166.22 (median: US$200.99) for inpatients with no complications, chronic complications, and acute +
chronic complications, respectively. Total and individual costs were significantly less for patients without
complications than for those with the two types of complications (p < 0.001). (3) Mean total costs per patient were
US$225.40 ± 115.32 (median: US$200.34), US$221.25 ± 177.64 (median: US$170.05), and US$275.18 ± 193.14 (median:
US$217.91) for inpatients with microvascular complications, macrovascular complications, and microvascular +
macrovascular complications, respectively. Total costs were significantly higher for patients with microvascular +
macrovascular complications than for those with other types of chronic complications (p < 0.001). (4) Drugs were
the greatest expense for patients, and the least expensive treatment was nursing care.
Conclusions: Medical insurance status, age, and type of complication may help to predict LOS for patients with
type 2 diabetes in Hubei Province, China. The total and individual costs for patients with complications were higher
than for those without, and hospitalization expenses posed a heavy burden. Efforts should be made to reduce the
financial impact on patients by integrating the medical insurance system of urban and rural areas, and by reducing
the risk of complications, especially microvascular complications.
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Background
With global industrialization, urbanization, and modernization,
the number of people afflicted with type 2 diabetes is
growing year by year, with a projected increase from
current estimates of 240 million, 6% of adults, affected
to some 380 million, or 7% of adults, by 2025 [1]. In de-
veloping countries, a low level of health literacy and
rapid economic growth are expected to continue to
lead to higher prevalence of the disease. According to
data from the International Diabetes Federation, be-
tween 2010 and 2030, there will be a 69% increase in
numbers of adults with diabetes in developing coun-
tries, with 36% of the anticipated total global increase
of 154 million people with diabetes projected to occur
in India and China alone [2].
In recent years, huge changes have been taking place
in Chinese society in terms of lifestyle and diet [3, 4]. In-
crease in physical inactivity, unhealthy eating habits,
obesity, and smoking have led to widespread incidence
of diabetes [5, 6]. According to an epidemiological study
of diabetes in China, the age-standardized prevalence of
total diabetes and prediabetes were 9.7 and 15.5%,
respectively, accounting for 92.4 million adults with
diabetes and 148.2 million adults with prediabetes [7].
In China, the treatment of patients with diabetes has
created significant problems for the social healthcare
system. A systematic review of the direct economic bur-
den of type 2 diabetes in China showed that the direct
medical cost increased from US$250 million in 1993 to
US$8.65 billion in 2008. The annual total inpatient cost
increased from US$30 million in 1993 to US$3.13 billion
in 2007, with an average annual growth rate of 19.90%,
which was more than the average annual growth rate of
the gross domestic product (GDP (12.77%) and national
health expenditures (12.88%) from 1993 to 2003 [8].
Inpatient costs were a substantial portion of health
expenditures and were comprised of both direct and in-
direct costs; direct costs included cost of diagnosis and
treatment of diabetes and its complications, and indirect
costs represented productive losses resulting from pro-
longed length of stay (LOS), temporary or permanent
disability, and premature death. This has been the sub-
ject of much research globally, but few studies have been
carried out in Hubei Province, China. Therefore, asses-
sing diabetic inpatients’ LOS and hospitalization ex-
penses to reflect the patients’ burden was both necessary
and urgent. This study aimed to estimate the LOS and
direct costs of inpatients by analysing data on admission
characteristics and a variety of complications and pro-
vide some suggestions for reducing the financial burden
associated with type 2 diabetes.
A number of previous studies of LOS and direct costs
of type 2 diabetes and its complications have been made
[9, 10]. However, they failed to relate to the content of
these two aspects simultaneously [11, 12] and offered lit-
tle analysis of direct costs with regard to the various
types of complications in type 2 diabetes. The most
prominent feature of this study was that the information
of direct costs was explored from the perspectives of no
complications, chronic complications (microvascular
complications, macrovascular complications, and micro-
vascular +macrovascular complications), acute compli-
cations, and acute + chronic complications.
Methods
Data source and sample inclusion/exclusion criteria
The study was carried out in Zhongnan Hospital, a large
tertiary general hospital located in the capital of Hubei
Province, China. Data on inpatients between April 1,
2013, and March 31, 2014, whose principal discharge
diagnosis was type 2 diabetes were obtained from the
hospital information system (HIS), with diagnosis of type
2 diabetes determined in accordance with World Health
Organization guidelines [13]. Criteria for inclusion in
this study were the following: (1) both the main dis-
charge diagnosis and secondary diagnosis were type 2
diabetes or its complications, or the main discharge
diagnosis ICD-10 coding was E11; (2) age ≥18 years.
Exclusion criteria were the following: (1) gestational dia-
betes; (2) neonatal diabetes; (3) transfer treatment; (4)
deficits with primary data; (5) non-diabetic complica-
tions such as malignant tumours, fractures, and gastric
ulcers. For inpatients undergoing two or more hospitali-
zations, each hospitalization was studied as a separate
case, with our research focused on diabetic cases. The
analysis ultimately consisted of 1528 cases.
Data collection, study parameters, and definitions
Inpatients’ medical record information was exported to
Microsoft Excel from the HIS (Additional file 1) and
included (1) basic information such as hospitalization
number, medical record number, type of medical insur-
ance, name, gender, age, occupation, method of admission,
admission time, discharge time, LOS, admission diagnosis,
main discharge diagnosis, and other discharge diagnosis;
(2) cost information for drugs, accommodation, imaging,
therapeutics, laboratory analysis, sanitary materials, diag-
nostics, and nursing care. Information in Excel was pre-
liminarily selected according to the inclusion and
exclusion criteria and the above-mentioned information
was preserved. Setting the year 2013 as the standard,
the hospitalization costs were adjusted using China’s
consumer price index in order to take into account the
influence of inflation on health care costs. Inpatients
were classified into four groups according to the type
of complications: no complications, chronic complica-
tions, acute complications, and acute + chronic compli-
cations. Chronic complications were further subdivided
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into three categories: microvascular complications,
macrovascular complications, and microvascular +
macrovascular complications. Diabetes related compli-
cations included in the analysis were identified based
on the ICD-10 codes of complications [14] and classified
as either (1) acute, including coma with or without ketoa-
cidosis, hyperosmolar coma, hypoglycaemic coma, hyper-
glycaemic coma, acidosis, and ketoacidosis (http://
apps.who.int/classifications/icd10/browse/2010/en#/E10–
E14), or (2) chronic, including macrovascular complica-
tions (acute myocardial infarction, angina pectoris,
stroke, and non-traumatic amputation and foot ulcers)
and microvascular complications (various levels of ne-
phropathy [i.e., microalbuminuria, clinical proteinuria and
chronic renal failure], retinopathy [i.e., background and
proliferative retinopathy, macular edema, cataracts, and
blindness], and peripheral neuropathy [11]).
Statistical analysis
Numeric variables were reported as Mean ± standard devi-
ation (SD), Median/25th–75th percentile, and categorical
variables were described as both numbers and percentages.
Because LOS and hospitalization costs did not con-
form to the normal distribution, the Mann–Whitney U
test (with 2 subgroups) and Kruskal-Wallis test (with
multiple subgroups) were used for a preliminary explor-
ation of factors associated with LOS in univariate ana-
lysis and to evaluate the distributions of hospitalization
costs between subgroups. Multiple linear regression was
used to select variables which significantly predicted
LOS. To avoid overfitting the model, variables found to
be significant (p <0.10, inclusion criteria) in the univari-
ate analysis were included.
Data filtering was performed using Excel and analyses
were carried out using IBM SPSS Statistics 20. P < 0.05
was considered to be statistically significant.
Results
Demographic, clinic characteristics of the study
population
A total of 1528 patients were included in the study. Of
them, 944 were men (61.78%), with a mean age of
61.78 years (median: 60 years), and mean LOS of
11.65 days (median: 10 days). Urban Employee Basic
Medical Insurance, Urban Resident Basic Medical Insur-
ance, and the NCMS covered 44.82% (n = 685) of pa-
tients, and 96.20% (n = 1470) patients were admitted as
outpatients. Most of the patients were retired (47.19%).
Data from Table 1 shows that most inpatients (81.74%)
had chronic complications (Table 1).
Univariate analysis result
The Mann–Whitney U test (with 2 subgroups) and
Kruskal-Wallis test (with multiple subgroups) showed
that no significant difference was found between LOS
and gender (p =0.056), mode of admission (p =0.057), or
year of admission (p =0.998). Age group, type of medical in-
surance, occupation, and type of complications (p < 0.001)
were significantly associated with LOS. Inpatients aged 90
and over, receiving public financial assistance, retired, and
without complications had a longer LOS than other mem-
bers within the group, their mean LOS were 19.94 ±
5.96 days, 14.19 ± 6.11 days, 12.54 ± 6.29 days, 15.43 ±
7.17 days, respectively (Table 2).
Multiple linear regression analysis
Age group, type of medical insurance, occupation, and
type of complications which were found to be statisti-
cally significant in the univariate analysis were predic-
tors, and the LOS was the outcome variable for analysis.
According to the multiple linear regression analysis of
LOS, it could be concluded that age group, type of med-
ical insurance, and complications were the factors asso-
ciated with LOS. Inpatients with NCMS had a longer
LOS than with Urban Resident Basic Medical Insurance.
Compared with inpatients aged 20–30 years, those aged
80–90 had a longer LOS. Moreover, inpatients aged 90
and over had the longest LOS. A significant difference
was found between LOS and complications as well.
Compared to inpatients without complications, inpa-
tients with chronic complications and with acute +
chronic complications had longer LOS (Table 3).
Cost differencess between various complications
The mean cost per patient was US$232.47, and the total
costs were US$159.72 ± 130.83, US$240.60 ± 166.58, and
US$247.98 ± 166.22 for inpatients with no complications,
chronic complications, and acute + chronic complica-
tions, respectively, as shown in Table 4. The distribution
of costs for total expenses, drugs, accommodation, im-
aging, laboratory analysis, diagnostics, and nursing care
were significantly different not only between inpatients
without complications and those with chronic complica-
tions but also between inpatients without complications
and those with acute + chronic complications (p < 0.001).
The distribution of costs for therapeutics and sanitary
materials were significantly different between the three
different types of complications (p < 0.001). We can con-
clude inpatients without complications spent less than
those with other types of complications on total costs
and on the various individual expenses. Drugs and la-
boratory analysis were found to be the greatest expenses,
and the least was nursing care (Table 4).
Cost differences between various chronic complications
Chronic complications in type 2 diabetes patients was
divided into three categories: microvascular, macrovas-
cular, and microvascular +macrovascular complications
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as shown in Table 5. The total costs were US$225.40 ±
115.32, US$221.25 ± 177.64, and US$ 275.18 ± 193.14,
respectively. The distribution of total costs and accom-
modation costs were significantly different between the
three categories (p < 0.001). The distribution of costs for
therapeutics and nursing care were significantly different
not only between inpatients with microvascular compli-
cations and with microvascular + macrovascular compli-
cations but also between inpatients with macrovascular
complications and with microvascular +macrovascular
complications (p < 0.001). The distribution of costs for
drugs, imaging, laboratory analysis, sanitary materials,
and diagnostics showed significant differences between
inpatients with macrovascular complications and with
microvascular complications as well as between inpatients
with macrovascular complications and with microvascular
+macrovascular complications (p < 0.001). From the per-
spective of the total costs, inpatients with microvascular +
macrovascular complications spent the most. Drugs and
laboratory analysis were the highest costs and nursing care
was the lowest (Table 5).
Discussion
LOS and demographic and clinical characteristics
Through this study, Wuhan, a medium-sized city in
China where LOS of inpatients with diabetes (means:
11.65 ± 6.13 days; median: 10.00 days) were slightly
shorter than those reported in Shantou, China (means:
Table 1 Demographic and clinical characteristics of the study population
Characteristics Mean ± SD or number Median or percentage 25th–75th percentile
Gender Male 944 61.78
Female 584 38.22








LOS 11.65 ± 6.13 10 8–15
Type of medical insurance Urban Resident Basic Medical Insurance 41 2.68
Urban Employee Basic Medical Insurance 603 39.46
Other means of payment 23 1.51
Public expense 31 2.03
Private expense 789 51.64
NCMS 41 2.68
Mode of Admission Emergency 29 1.90
Outpatient 1470 96.20
Other 29 1.90
Year of admission 2013 724 47.38
2014 804 52.62





Complications No complications 164 10.73
Chronic complications 1249 81.74
Acute + chronic complications 115 7.53
Costs per patient 232.47 ± 164.95 185.00 142.04–272.18
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13.91 days; median: 10.00 days) [15] but slightly longer
than those found abroad (means: 8.2 days) [12]. These
discrepancies may stem from the type and grade of hos-
pital, the standard charges, the conditions for care, and
the social and cultural environment [16, 17].
The findings of the multiple linear regression analysis
were unlike much previous research [18, 19] in that
people with the new cooperative medical scheme had a
longer LOS than people with Urban Resident Basic
Medical Insurance and with Urban Employee Basic
Medical Insurance. Despite a relatively high coverage of
medical insurance in China, the coverage provided by
different types of social medical insurance in the country
varies greatly. At present, Urban Employee Basic Med-
ical Insurance, as an earlier developed and more mature
social medical insurance in China, is superior to other
social medical insurance plans in its coverage and cost
in terms of deductible and rate of reimbursement. The
difference mentioned above is the main reason why
Urban Employee Basic Medical Insurance would in-
crease the cost of hospitalization and the LOS. However,
our study draws different conclusions, which can be ex-
plained as follows: Zhongnan Hospital, as a large tertiary
general hospital, serves not only the immediate urban
area but also the rural area which surrounds it. The
current grading clinics allow patients living in rural
areas, most of whom are enrolled in the new cooperative
medical schemes, to come to Zhongnan Hospital for
further treatment of more serious conditions. Thus, the
results of this study showed that the LOS of patients
with the new cooperative medical scheme were longer.
From these results, we can conclude that establishing an
Table 2 Factors associated with LOS by univariate analysis
Factors Mean days Median days P-value
Gender Male 11.40 ± 6.04 10.00 (7.00–14.00) 0.056
Female 12.04 ± 6.27 11.00 (8.00–15.00)
Age group 20~ 9.06 ± 3.79 9.00 (6.00–12.75) <0.001
30~ 10.00 ± 5.63 9.00 (7.00–10.50)
40~ 10.95 ± 6.21 10.00 (7.00–13.00)
50~ 9.83 ± 5.09 9.00 (7.00–13.00)
60~ 10.71 ± 5.12 10.00 (8.00–13.00)
70~ 12.45 ± 5.99 11.00 (9.00–15.00)
80~ 15.67 ± 6.73 16.00 (11.00–21.00)
90~ 19.94 ± 5.96 21.00 (16.75–23.25)
Type of medical insurance Urban Resident Basic Medical Insurance 10.31 ± 5.39 9.00 (7.00–11.00) <0.001
Urban Employee Basic Medical Insurance 10.14 ± 4.84 9.00 (7.00–12.00)
Other 13.30 ± 5.41 13.00 (11.00–17.00)
Public expense 14.19 ± 6.11 15.00 (10.00–19.00)
Private expense 12.65 ± 6.74 12.00 (8.00–17.00)
NCMS 12.95 ± 7.15 11.00 (8.50–15.50)
Occupation Employee 10.95 ± 6.20 10.00 (7.00–15.00) <0.001
Student 12.00 ± 5.57 13.00 (6.00–)
Labourer 10.32 ± 5.26 9.00 (7.00–13.00)
Employed 12.54 ± 6.29 11.00 (8.00–16.00)
Unemployed 11.02 ± 5.94 10.00 (8.00–13.00)
Mode of Admission Emergency 10.62 ± 7.81 9.00 (4.50–13.00) 0.057
Outpatient 11.68 ± 5.95 10.00 (8.00–15.00)
Other 11.03 ± 11.33 9.00 (2.00–14.50)
Year of admission 2013 11.67 ± 6.31 10.00 (8.00–14.00) 0.998
2014 11.62 ± 5.97 10.00 (8.00–15.00)
Complications No complications 15.43 ± 7.17 15.50 (10.00–22.00) <0.001
Chronic complications 11.23 ± 5.84 10.00 (8.00–14.00)
Acute + chronic complications 10.74 ± 5.81 10.00 (7.00–13.00)
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Table 3 Factors associated with LOS by multiple linear regression analysis
Factors Reference group ß Std. Error 95% C.I P-value
Lower Upper
Gender
Female Male 0.165 0.319 −0.459 0.790 0.604
Age group
30~ 20~ 1.339 1.761 −2.112 4.790 0.447
40~ 2.091 1.612 −1.069 5.252 0.195
50~ 0.591 1.616 −2.577 3.758 0.715
60~ 1.325 1.642 −1.893 4.543 0.420
70~ 2.856 1.645 −0.368 6.081 0.083
80~ 5.161 1.671 1.887 8.435 0.002
90~ 8.328 2.157 4.101 12.555 0.001
Type of medical insurance
Urban Employee Basic Medical Insurance Urban Resident Basic Medical Insurance −0.050 0.921 −1.856 1.756 0.957
Other 2.541 1.486 −0.372 5.454 0.087
Public expense 2.250 1.383 −0.460 4.961 0.104
Private expense 1.489 0.919 −0.311 3.290 0.105
NCMS 3.053 1.265 0.574 5.531 0.016
Occupation
Labourer Employee 0.118 0.577 −1.014 1.249 0.839
Retired 0.843 0.483 −0.104 1.790 0.081
Unemployed 0.506 0.471 −0.416 1.429 0.282
Mode of Admission
Outpatient Emergency 1.331 1.079 −0.784 3.445 0.217
Other 0.348 1.507 −2.605 3.301 0.817
Complications
Chronic complications No complications −1.678 0.548 −2.751 −0.605 0.002
Acute + chronic complications −2.475 0.753 −3.951 −0.998 0.001
The occupation “student” was not included in the multiple linear regression analysis because the sample size was limited to 3
Table 4 Hospitalization costs of type 2 diabetes in patients with various complications
Hospitalization
costs
No complications Chronic complications Acute + chronic complications P-value
Mean ± SD Median Mean ± SD Median Mean ± SD Median
Total costs 159.72 ± 130.83 135.33 (92.03–184.28) 240.60 ± 166.58 192.09 (147.81–282.30)a 247.98 ± 166.22 200.99 (155.47–286.39)b <0.001
Drugs 68.69 ± 75.18 57.84 (27.98–84.92) 111.60 ± 84.44 89.60 (61.67–138.62)a 115.59 ± 82.89 95.45 (62.99–135.40)b <0.001
Accommodation 10.28 ± 12.35 7.71 (4.24–12.95) 14.90 ± 19.19 11.64 (8.81–15.80)a 13.28 ± 6.99 11.11 (8.81–16.26)b <0.001
Imaging 16.48 ± 14.61 15.03 (4.98–23.06) 25.65 ± 19.87 22.35 (13.26–33.55)a 23.93 ± 17.13 22.06 (11.15–31.75)b <0.001
Therapeutics 14.41 ± 36.90 6.63 (2.32–11.38) 27.12 ± 48.69 10.92 (5.79–20.07)a 31.15 ± 49.19 13.84 (8.48–24.89)bc <0.001
Lab analysis 32.85 ± 22.34 31.55 (19.01–46.50) 44.62 ± 26.04 39.72 (28.33–56.05)a 44.44 ± 25.33 38.76 (25.68–58.61)b <0.001
Sanitary
materials
5.25 ± 5.69 3.78 (1.84–6.81) 11.48 ± 62.34 5.31 (3.35–7.77)a 14.31 ± 32.36 6.54 (4.31–9.76)bc <0.001
Diagnostics 1.55 ± 1.08 1.42 (0.75–2.06) 2.24 ± 1.06 2.06 (1.53–2.68)a 2.27 ± 1.01 2.07 (1.53–2.87)b <0.001
Nursing care 1.09 ± 1.77 0.76 (0.47–1.32) 1.65 ± 1.45 1.15 (0.86–1.91)a 1.82 ± 1.55 1.23 (0.85–2.10)b <0.001
A Dunn’s nonparametric comparison for post hoc testing after a Kruskal-Wallis test were performed and indicated significant differences between groups of no
complications and chronic complications, no complications and acute + chronic complications, and chronic complications and acute + chronic complications, as
illustrated a, b, c respectively in Table 4
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unified basic medical insurance system for urban and
rural residents to guarantee basic medical insurance
rights and interests, promote social fairness, and encour-
age urban–rural coordinated development is needed.
China is currently exploring a new way to integrate the
medical insurance system of urban and rural areas [20].
In addition, the multiple linear regression analysis
showed another result different from many studies
which indicated that people without complications had a
longer LOS than people with chronic complications and
acute + chronic complications [21–23]. The mean LOS
were 11.23 ± 5.84 and 10.74 ± 5.81 days respectively for
patients with chronic complications and acute + chronic
complications as opposed to 15.43 ± 7.17 days for pa-
tients without complications. One possible reason for
this is that most inpatients without complications were
hospitalized for the first time, or this was the first time
the disease had been diagnosed, so they paid more atten-
tion to the disease and accepted longer hospitalization in
order to control the development of the disease. How-
ever, patients with complications may have been more
likely to receive a shorter hospitalization and then main-
tain drug treatment at home.
Costs and various type of complications
The result of the study showed that the average per
patient cost of diabetes was US$232.47 and the median
cost was US$185.00. This is different from that found in
some other parts of China and abroad [24, 25]. For in-
stance, the average cost per patient was far less than that
in Europe and the United Arab Emirates [11], but was
slightly higher than the US$152 per patient in Iran [26].
China is a developing country, with its own unique na-
tional conditions, medical and health service systems, hos-
pital grades and settings, and these may be responsible for
the discrepancy in average per patient cost. According to a
survey of resident income in China, GDP per capita was
US$4410.59 (29,992 RMB, with an exchange rate for US$
to RMB of 1:6.8 in 2010) [27]. The average hospitalization
cost for diabetic patients was 5.27% of the GDP per capita
and 55.35% of the per capital expenditure for health care
(http://data.worldbank.org.cn/indicator/SH.XPD.PCAP/co
untries). This means diabetes is a huge burden both for
residents and for the health care system. Other studies
have come to the same conclusion [28].
This study found that costs for inpatients with complica-
tions were higher than for patients without complications,
and numerous studies have drawn similar conclusions
[29, 30]. This study also found total costs for patients
with microvascular + macrovascular complications were
higher than those for patients with microvascular com-
plications alone. Moreover, this research showed that
patients with macrovascular complications spent the
least. These findings which were completely contrary to
the conclusions of the study conducted in Europe and the
United Arab Emirates, which found that patients with
microvascular +macrovascular complications spend the
most, followed by those with macrovascular complica-
tions, in that study, patients with microvascular compli-
cations spent the least [11]. As the disease progresses, a
series of complications will inevitably occur, either with
regard to personal health or in terms of the social eco-
nomic burden, preventing and controlling the complica-
tions of diabetes, especially microvascular complications,
are essential.
Regardless of the kind of complication, drugs were the
highest type of cost and nursing care the least. Therefore,
in order to reduce the burden of the disease in patients
with type 2 diabetes, measures should be taken to reduce
drug costs in conjunction with the implementation of
drug price reform policies in Hubei Province. Moreover,
because diabetes is a metabolic disease, in addition to
access to affordable medication, health education and
lifestyle interventions are also very important, as many
studies have shown [31, 32]. In this way, both LOS and
hospital costs would decrease.
Table 5 Hospitalization costs of type 2 diabetes in patients with various chronic complications
Hospitalization
costs
Microvascular Macrovascular Microvascular + macrovascular P-value
Mean ± SD Median Mean ± SD Median Mean ± SD Median
Total costs 225.40 ± 115.32 200.34 (151.00–263.24) 221.25 ± 177.64 170.05 (134.81–255.11)a 275.18 ± 193.14 217.91 (158.94–345.02)bc <0.001
Drugs 109.11 ± 67.82 94.80 (65.25–137.20) 99.60 ± 76.64 80.26 (57.07–119.78)a 125.87 ± 103.22 96.08 (63.04–164.70)c <0.001
Accommodation 13.12 ± 7.55 11.72 (8.99–15.09) 13.24 ± 13.98 10.11 (7.71–15.42)a 18.37 ± 29.02 12.38 (9.91–17.73)bc <0.001
Imaging 28.19 ± 19.55 24.26 (15.97–35.40) 21.84 ± 16.31 19.85 (10.84–29.24)a 26.74 ± 22.65 22.61 (11.48–35.99)c <0.001
Therapeutics 16.08 ± 20.87 10.76 (5.71–16.61) 29.55 ± 54.91 10.33 (5.31–19.92) 36.14 ± 59.49 11.71 (6.47–29.3)bc 0.005
Lab analysis 45.96 ± 25.19 40.30 (28.55–58.62) 40.44 ± 19.78 37.33 (27.69–50.51)a 47.30 ± 31.32 41.37 (28.94–60.36)c 0.007
Sanitary
materials
7.14 ± 10.02 5.52 (3.69–7.46) 12.15 ± 95.75 4.64 (2.84–7.01)a 15.31 ± 49.03 6.02 (3.59–9.15)c <0.001
Diagnostics 2.22 ± 0.95 2.10 (1.69–2.62) 2.08 ± 0.99 1.87 (1.50–2.62)a 2.40 ± 1.21 2.25 (1.69–2.87)c <0.001
Nursing care 1.34 ± 1.17 1.12 (0.85–1.42) 1.55 ± 1.36 1.05 (0.76–1.87) 2.08 ± 1.69 1.63 (0.96–2.62)bc <0.001
A Dunn’s nonparametric comparison for post hoc testing after a Kruskal-Wallis test were performed and indicated significant differences between groups of
microvascular complications and macrovascular complications, microvascular complications and microvascular + macrovascular complications, and macrovascular complications
and microvascular +macrovascular complications, as illustrated a, b, c respectively in Table 5
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Limitations
Because this study was conducted with data from a
single hospital, findings might have been different in
other parts of the country or in other types of hospitals.
In addition, the data was limited to the period between
April 1, 2013, and March 31, 2014, a relatively short
time span; thus, a continuous trend comparison could
not be made. Also, for patients undergoing two or more
hospitalizations, each hospitalization was studied as a
separate case, which may have led to an underestimate
of hospital costs. Moreover, some cardiovascular diseases
are not limited to patients with diabetes but may occur
before diabetes, so some of the costs might not have
been caused by diabetes, leading to an overestimation of
hospital costs. Finally, the data for demographic and
clinic characteristics were limited (e.g., the results of
laboratory tests), if more data for demographic and clin-
ical characteristics had been available, this research
would be more substantial.
Conclusions
The LOS for patients with diabetes in China were found
to be longer than those in foreign countries. It should be
appropriate to take measures, such as integrating the
medical insurance system of urban and rural areas as
well as monitoring and educating patients at home.
Overall, the costs for patients with complications were
higher than for patients without complications, so pre-
venting and controlling the complications of diabetes is
imperative, especially microvascular complications.
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